特一药业集团股份有限公司2025年第三季度报告

Core Viewpoint - The company emphasizes the accuracy and completeness of its financial disclosures and reports, ensuring no misleading statements or significant omissions are present [2][9]. Financial Data Summary - The third-quarter financial report has not been audited [3][8]. - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. - Non-recurring gains and losses are not applicable, and there are no other items classified as non-recurring [3]. Shareholder Information - As of September 30, 2025, the company repurchased 13,729,618 shares, accounting for 2.68% of the total share capital, with a total expenditure of approximately RMB 101.19 million [5]. - The highest repurchase price was RMB 8.03 per share, and the lowest was RMB 6.79 per share [5]. Board Meeting Details - The sixth board meeting was held on October 23, 2025, with all six directors present, and the meeting complied with relevant laws and regulations [10]. - The board approved the third-quarter report during the meeting, which had been reviewed and agreed upon by the audit committee [11][12].